Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen stock markets have announced significant updates, including changes in financing, business performance, and strategic decisions, which may impact investor sentiment and market dynamics [1]. Financing and Restructuring - Guanhao Biological has withdrawn its application for refinancing, leading to the termination of the review process by the Shenzhen Stock Exchange [3]. - Jinhongshun has terminated its major asset restructuring plan due to a lack of consensus among parties involved [6]. - Yuyuan Co. plans to issue bonds not exceeding 40 billion yuan to adjust its debt structure and replenish working capital [23]. Business Performance and Uncertainties - Aored has highlighted significant uncertainties in its computing power leasing services due to heavy asset investment and potential market fluctuations [4]. - Guoyao Modern intends to publicly transfer 51% of its subsidiary Guoyao Hason's shares, as the subsidiary has been underperforming with continuous losses since 2021 [5]. - Chengbang Co. reported that its subsidiary, Xinchun Electronics, has a small business scale and faces intense competition in the semiconductor storage industry, with projected revenues of 111 million yuan and a net profit of 933,800 yuan for 2024 [9]. Stock Market Activity - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock trading resuming on July 1 [7]. - Changcheng Military Industry reported significant stock price volatility, with a cumulative increase of over 100% in the last 10 trading days, indicating potential irrational market behavior [8]. Earnings Forecasts - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, recovering from a loss in the previous year, driven by international business growth [12]. - Taotao Vehicle anticipates a net profit increase of 70.34% to 97.81% for the same period, reflecting strong sales performance [13]. - Weichai Heavy Machinery projects a net profit increase of 40% to 60%, benefiting from industry policy support and demand growth [15]. Major Contracts and Projects - China Railway has won contracts for overseas construction projects totaling approximately 5.343 billion yuan [17]. - Zhonggong International has signed a 175 million yuan engineering consulting service contract [18]. - Hezhan Energy has entered into a 177 million yuan contract for the sale of steel-concrete towers [19].

证券代码：600420 证券简称：国药现代 公告编号：2025-055 本次预挂牌仅为信息预披露，不构成交易行为。交易对手尚不明确，尚 未签署交易合同，无履约安排。 本次控股子公司股权公开转让事项尚需获得上级主管单位中国医药集团 有限公司审批。 一、交易概述 为推进实施公司中长期战略规划，优化资源配置，提高公司资产的运营效率， 公司拟转让控股子公司国药哈森 51%股权，并根据国有资产管理的有关规定，将 在上海联合产权交易所进行预挂牌。转让底价将在正式挂牌转让前，以资产评估 机构出具的评估结果为依据确定。公司已于 2025 年 6 月 30 日召开总裁办公会审 议通过上述股权转让事项，本次交易尚需获得上级主管单位中国医药集团有限公 司审批。根据《上海证券交易所股票上市规则》及公司《章程》，该事项无需提 交公司董事会及股东会审议。 上海现代制药股份有限公司 关于拟公开转让控股子公司股权预挂牌的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海现代制药股份有限公司（以下简称公司）拟转让公司所持有的上海 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-054 药品名称：培哚普利吲达帕胺片 上海现代制药股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）收到国家药品监督管理局核准签发的培哚普利 吲达帕胺片《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 剂型：片剂 规格：每片含培哚普利叔丁胺 4mg（按 C₁₉H₃₂N₂O₅·C₄H₁₁N 计）和吲达帕 胺 1.25mg 注册分类：化学药品 4 类 证书编号：2025S01937 药品批准文号：国药准字 H20254655 药品生产企业：国药集团工业有限公司 上市许可持有人：国药集团工业有限公司 申请事项：药品注册（境内生产） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及市场情况 培哚普利吲达帕胺片是由培哚普利叔丁胺和吲 ...

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), is planning to transfer 51% equity of its subsidiary Shanghai Modern Harsen (商丘) Pharmaceutical Co., Ltd. to optimize resource allocation and improve asset operational efficiency [1] Group 1: Company Actions - The company intends to conduct a public transfer of the subsidiary's equity at the Shanghai United Assets and Equity Exchange [1] - The transaction counterpart is currently unspecified, and no transaction contract has been signed yet [1] - The equity transfer is subject to approval from the higher authority, China National Pharmaceutical Group Co., Ltd. [1] Group 2: Financial Performance - For the period from January to April 2025, Shanghai Modern Harsen reported revenue of 101 million yuan and a net loss of 19.898 million yuan [1]

Core Viewpoint - The approval of Perindopril Indapamide tablets by the National Medical Products Administration enhances the product portfolio of the company in the cardiovascular field and strengthens its market competitiveness [1] Group 1 - The company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., received the drug registration certificate for Perindopril Indapamide tablets [1] - The drug is a compound tablet consisting of Perindopril tert-butylamine and Indapamide, intended for the treatment of primary hypertension in adults [1] - The projected sales revenue for Perindopril Indapamide tablets in public medical institutions and urban pharmacies across the country in 2024 is estimated to be 269 million yuan [1] Group 2 - The cumulative research and development investment for this project by the company amounts to approximately 18.568 million yuan [1] - The approval of this drug will enrich the company's formulation product line in the cardiovascular sector [1] - The new product is expected to enhance the company's competitiveness in the market [1]

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

证券代码：600420 证券简称：国药现代 公告编号：2025-053 上海现代制药股份有限公司 关于全资子公司获得化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）收到国家药品监督管理局核准签发的《化学原 料药上市申请批准通知书》，批准原料药盐酸戊乙奎醚上市申请，现将相关情况 公告如下： 一、化学原料药基本信息 化学原料药名称：盐酸戊乙奎醚 登记号：Y20230001255 通知书编号：2025YS00511 化学原料药注册标准编号：YBY65962025 包装规格：0.1kg/袋，0.2kg/袋，0.5kg/袋，1kg/袋 生产企业：国药集团工业有限公司廊坊分公司 企业地址：廊坊经济技术开发区创业路 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、药品研发及市场情况 盐酸戊乙奎醚为选择性抗胆碱药 ...

Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420), has received approval from the National Medical Products Administration for the marketing application of the raw material drug, Pentazocine Hydrochloride, which is widely used for pre-anesthetic medication and emergency treatment of organophosphate poisoning [1] Group 1 - The approval allows the company to market Pentazocine Hydrochloride, expanding its product offerings in the pharmaceutical sector [1] - The total research and development investment for this project amounts to approximately RMB 4.805 million [1] - The current approval is not expected to have a significant impact on the company's operating performance for the period [1]

General Provisions - The purpose of the articles of association is to protect the legal rights of the company, shareholders, employees, and creditors, and to regulate the company's organization and behavior according to relevant laws [1][3] - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations, with a registered capital of RMB 1,341,172,692 [2][10] - The company was approved for its initial public offering of 33,000,000 shares on June 16, 2004, and is listed on the Shanghai Stock Exchange [1][3] Business Objectives and Scope - The company's business objective is to utilize advanced scientific technology to continuously develop and produce new pharmaceutical products and processes, aiming to become a technology enterprise with significant economic benefits [4] - The registered business scope includes the manufacturing of pharmaceuticals and health products, sales of pharmaceuticals and medical devices, and various technology development and consulting services [4][5] Party Committee - The company has established a Communist Party organization to conduct party activities, providing necessary conditions for such activities [5] - The Party Committee is responsible for leading the company’s political construction and ensuring the implementation of major decisions from the Party [5][6] Share Issuance - The company's shares are issued in the form of stocks, adhering to principles of openness, fairness, and justice, with equal rights for each share of the same category [6][7] - The total number of ordinary shares approved for issuance at the company's establishment was 54,191,940 shares, with specific contributions from founding entities [7][10] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, supervision of company operations, and access to company documents [15][16] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not abuse their rights to harm the company or other shareholders [20][21] Shareholder Meetings - The company holds annual and extraordinary shareholder meetings, with the annual meeting required to be held within six months after the end of the previous fiscal year [57][58] - Shareholder meetings must be convened in accordance with legal procedures, and shareholders holding more than 10% of shares can request extraordinary meetings [61][63] Decision-Making and Voting - Major decisions, including capital increases, mergers, and significant transactions, require approval from the shareholder meeting [53][54][56] - Voting procedures must be transparent, and shareholders can appoint proxies to attend and vote on their behalf [75][76]

Core Points - The document outlines the governance structure and responsibilities of independent directors at Shanghai Modern Pharmaceutical Co., Ltd, aiming to protect minority shareholders' rights and ensure the company's proper operation [2][3][19] Group 1: Independent Director Definition and Responsibilities - Independent directors are defined as those who do not hold any other positions in the company and have no direct or indirect interests that could affect their independent judgment [2][3] - They are obligated to act in good faith and diligence towards the company and all shareholders, participating in decision-making, supervision, and providing professional advice [2][3][4] Group 2: Qualifications and Independence of Independent Directors - Candidates for independent directors must have basic knowledge of listed company operations and at least five years of relevant work experience in law, economics, finance, or management [3][5] - Specific disqualifications for independent directors include holding significant shares in the company or being related to major shareholders, among other criteria [3][4][6] Group 3: Nomination and Election Process - Independent director candidates can be proposed by the board or shareholders holding at least 1% of the company's shares, and the election must be conducted at a shareholders' meeting [5][6][7] - The proportion of independent directors on the board must not be less than one-third, including at least one accounting professional [5][6] Group 4: Duties and Powers of Independent Directors - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing objective advice to enhance decision-making [21][22] - They have the authority to independently hire external advisors, propose meetings, and publicly solicit shareholder opinions [22][23] Group 5: Reporting and Communication - Independent directors must submit annual reports detailing their attendance at meetings, participation in committees, and communication with minority shareholders [34][35] - They are required to maintain communication with the company and ensure transparency in their activities and findings [12][13][14] Group 6: Compensation and Insurance - The company is required to provide appropriate compensation to independent directors, which must be disclosed in the annual report [50] - A liability insurance system may be established to protect independent directors from risks associated with their duties, excluding liabilities arising from legal violations [51]